TACC3 as a Prognostic Marker in Breast Carcinoma, an Immunohistochemical study in Qena University Hospitals
El Dosoky, M., Fadel, S., Abdel Shafy, M., Mohamed, A. (2025). TACC3 as a Prognostic Marker in Breast Carcinoma, an Immunohistochemical study in Qena University Hospitals. EKB Journal Management System, 8(1), 104-116. doi: 10.21608/svuijm.2024.314866.1969
Mahmoud I. El Dosoky; Sabah M. Fadel; Mohamed Abdel Shafy; Asmaa M. Mohamed. "TACC3 as a Prognostic Marker in Breast Carcinoma, an Immunohistochemical study in Qena University Hospitals". EKB Journal Management System, 8, 1, 2025, 104-116. doi: 10.21608/svuijm.2024.314866.1969
El Dosoky, M., Fadel, S., Abdel Shafy, M., Mohamed, A. (2025). 'TACC3 as a Prognostic Marker in Breast Carcinoma, an Immunohistochemical study in Qena University Hospitals', EKB Journal Management System, 8(1), pp. 104-116. doi: 10.21608/svuijm.2024.314866.1969
El Dosoky, M., Fadel, S., Abdel Shafy, M., Mohamed, A. TACC3 as a Prognostic Marker in Breast Carcinoma, an Immunohistochemical study in Qena University Hospitals. EKB Journal Management System, 2025; 8(1): 104-116. doi: 10.21608/svuijm.2024.314866.1969

TACC3 as a Prognostic Marker in Breast Carcinoma, an Immunohistochemical study in Qena University Hospitals

SVU-International Journal of Medical Sciences
Article 10, Volume 8, Issue 1, January 2025, Page 104-116  XML PDF (754.38 K)
Document Type: Original research articles
DOI: 10.21608/svuijm.2024.314866.1969
View on SCiNiTO View on SCiNiTO
Authors
Mahmoud I. El Dosoky email orcid 1; Sabah M. Fadel2; Mohamed Abdel Shafyorcid 3; Asmaa M. Mohamed2
1Pathology Department, Faculty of Medicine, South Valley University, Qena, Egypt.
2Pathology Department, Faculty of Medicine, Assuit University, Assuit, Egypt.
3General Surgery Department, Faculty of Medicine, South Valley University, Qena, Egypt.
Abstract
Background: Transforming acidic coiled-coil 3 (TACC3) protein is linked to several forms of human cancer. Yet, its precise role in breast cancer (BC) remains unclear.
Objectives: This study aims to evaluate the immunohistochemical (IHC) expression of TACC3 in BC and its correlation with clinicopathological features and hormonal receptors expression.
Patients and methods: TACC3 was immunohistochemically examined in 60 cases of primary BC from the pathology lab at Qena University Hospital (during the period from April 2021 to April 2023). Alongside this analysis, the patients were also assessed for estrogen receptor, progesterone receptor, HER2/neu, and ki67 index.
Results: A statistically significant association between TACC3 with age, lymph node metastasis, tumor necrosis, ER, and PR expression (p values = 0.049, 0.020, 0.006, 0.042 and 0.006, respectively) was detected. There was no statistically significant difference between TACC3 and tumor stage, lymphovascular emboli, perineural invasion, histological type, HER-2 status and Ki67 (p value > 0.05).
Conclusion: These results suggest that TACC3 may be of valuable prognostic value BC. Furthermore, TACC3 might be a potential candidate for targeted therapy.
Keywords
TACC3; Breast cancer; Estrogen receptor; Progesterone receptor
Statistics
Article View: 199
PDF Download: 99